Perampanel in the management of partial-onset seizures: a review of safety, efficacy, and patient acceptability

References

• WatkinsJCJaneDEThe glutamate storyBr J Pharmacol2006147suppl 1S100S10816402093
   PubMed Web of Science ®Google Scholar
• MeldrumBSRogawskiMAMolecular targets for antiepileptic drug developmentNeurotherapeutics200741186117199015
   PubMed Web of Science ®Google Scholar
• HarrisLWSharpTGartlonJJonesDNCHarrisonPJLong-term behavioural, molecular and morphological effects of neonatal NMDA receptor antagonismEur J Neurosci20031861706171014511349
   PubMed Web of Science ®Google Scholar
• JanaćBSelakovićVRadenovićLTemporal patterns of motor behavioural improvements by MK-801 in Mongolian gerbils submitted to different duration of global cerebral ischemiaBehav Brain Res20081941727818655805
   PubMed Web of Science ®Google Scholar
• WedzonyKFijalKMackowiakMChocykAZajaczkowskiWImpact of postnatal blockade of N-methyl-D-aspartate receptors on rat behavior: a search for a new developmental model of schizophreniaNeuroscience200815341370137918434025
   PubMed Web of Science ®Google Scholar
• NabeshimaTMouriAMuraiRNodaYAnimal model of schizophrenia: dysfunction of NMDA receptor-signaling in mice following withdrawal from repeated administration of phencyclidineAnn N Y Acad Sci2006108616016817185514
   PubMed Web of Science ®Google Scholar
• FreedmanRSchizophreniaN Engl J Med2003349181738174914585943
   PubMed Web of Science ®Google Scholar
• CroucherMJCollinsJFMeldrumBSAnticonvulsant action of excitatory amino acid antagonistsScience198221645488999017079744
   PubMed Web of Science ®Google Scholar
• LöscherWHönackDThe novel competitive N-methyl-D-aspartate (NMDA) antagonist CGP 37849 preferentially induces phencyclidine-like behavioral effects in kindled rats: attenuation by manipulation of dopamine, alpha-1 and serotonin1A receptorsJ Pharmacol Exp Ther19912573114611531675288
   PubMed Web of Science ®Google Scholar
• SveinbjornsdottirSSanderJWUptonDThe excitatory amino acid antagonist D-CPP-ene (SDZ EAA-494) in patients with epilepsyEpilepsy Res19931621651748269915
   PubMed Web of Science ®Google Scholar
• AlbersGWAtkinsonRPKelleyRERosenbaumDMSafety, tolerability, and pharmacokinetics of the N-methyl-D-aspartate antagonist dextrorphan in patients with acute stroke. Dextrorphan Study GroupStroke19952622542587831698
   PubMed Web of Science ®Google Scholar
• LeesKRCerestat and other NMDA antagonists in ischemic strokeNeurology1997495 suppl 4S66S699371155
   PubMed Web of Science ®Google Scholar
• ChappellASSanderJWBrodieMJA crossover, add-on trial of talampanel in patients with refractory partial seizuresNeurology200258111680168212058100
   PubMed Web of Science ®Google Scholar
• SzabadosTGiglerGGacsályiIGyertyánILévayGComparison of anticonvulsive and acute neuroprotective activity of three 2,3-benzodiazepine compounds, GYKI 52466, GYKI 53405, and GYKI 53655Brain Res Bull200155338739111489346
   PubMed Web of Science ®Google Scholar
• ChapmanAGSmithSEMeldrumBSThe anticonvulsant effect of the non-NMDA antagonists, NBQX and GYKI 52466, in miceEpilepsy Res19919292961794356
   PubMed Web of Science ®Google Scholar
• YamaguchiSDonevanSDRogawskiMAAnticonvulsant activity of AMPA/kainate antagonists: comparison of GYKI 52466 and NBOX in maximal electroshock and chemoconvulsant seizure modelsEpilepsy Res19931531791847693450
   PubMed Web of Science ®Google Scholar
• ChenC-YMattLHellJWRogawskiMAPerampanel inhibition of AMPA receptor currents in cultured hippocampal neuronsPLoS One201499e10802125229608
   PubMed Web of Science ®Google Scholar
• CitraroRAielloRFrancoVDe SarroGRussoETargeting α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate receptors in epilepsyExpert Opin Ther Targets201418331933424387310
   PubMed Web of Science ®Google Scholar
• DiraniMNasreddineWAbdullaFBeydounASeizure control and improvement of neurological dysfunction in Lafora disease with perampanelEpilepsy Behav Case Rep20142164166
   Google Scholar
• HanadaTHashizumeYTokuharaNPerampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsyEpilepsia20115271331134021635236
   PubMed Web of Science ®Google Scholar
• GiglerGMóriczKAgostonMNeuroprotective and anticonvulsant effects of EGIS-8332, a non-competitive AMPA receptor antagonist, in a range of animal modelsBr J Pharmacol2007152115116017603549
   PubMed Web of Science ®Google Scholar
• Schulze-BonhageAPerampanel for epilepsy with partial-onset seizures: a pharmacokinetic and pharmacodynamic evaluationExpert Opin Drug Metab Toxicol20151181329133726111428
   PubMed Web of Science ®Google Scholar
• PatsalosPNThe clinical pharmacology profile of the new antiepileptic drug perampanel: a novel noncompetitive AMPA receptor antagonistEpilepsia2015561122725495693
   PubMed Web of Science ®Google Scholar
• European Medicines Agency EMA. Fycompa SPCPerampanel (Fycompa). Summary of Product Characteristics [updated November 13, 2013]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002434/WC500130815.pdf
   Google Scholar
• US Food and Drug Administration FDAClinical Pharmacologyreview2012 Reference ID: 3205587. Available from: http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM332052.pdf
   Google Scholar
• FrenchJAKraussGLBitonVAdjunctive perampanel for refractory partial-onset seizures randomized phase III study 304Neurology201279658959622843280
   PubMed Web of Science ®Google Scholar
• FrenchJAKraussGLSteinhoffBJEvaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305: Perampanel for Partial-Onset SeizuresEpilepsia201354111712522905857
   PubMed Web of Science ®Google Scholar
• KraussGLSerratosaJMVillanuevaVRandomized phase III study 306: adjunctive perampanel for refractory partial-onset seizuresNeurology201278181408141522517103
   PubMed Web of Science ®Google Scholar
• FrancoVCremaFIudiceAZaccaraGGrilloENovel treatment options for epilepsy: focus on perampanelPharmacol Res2013701354023287426
   PubMed Web of Science ®Google Scholar
• KraussGLBarMBitonVTolerability and safety of perampanel: two randomized dose-escalation studies: tolerability and safety of perampanelActa Neurol Scand2012125181521883097
   PubMed Web of Science ®Google Scholar
• KramerLDSatlinAKraussGLPerampanel for adjunctive treatment of partial-onset seizures: a pooled dose-response analysis of phase III studiesEpilepsia201455342343124605793
   PubMed Web of Science ®Google Scholar
• KraussGLPeruccaEBen-MenachemELong-term safety of perampanel and seizure outcomes in refractory partial-onset seizures and secondarily generalized seizures: results from phase III extension study 307Epilepsia20145571058106824867391
   PubMed Web of Science ®Google Scholar
• RektorIKraussGLBarMPerampanel Study 207: long-term open-label evaluation in patients with epilepsyActa Neurol Scand201212626326922913800
   PubMed Web of Science ®Google Scholar
• SteinhoffBJBen-MenachemERyvlinPEfficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studiesEpilepsia20135481481148923663001
   PubMed Web of Science ®Google Scholar
• SerratosaJMVillanuevaVKerlingFKasperBSSafety and tolerability of perampanel: a review of clinical trial dataActa Neurol Scand Suppl2013197303523480154
   PubMedGoogle Scholar
• FaulknerMAPerampanel: a new agent for adjunctive treatment of partial seizuresAm J Health Syst Pharm201471319119824429011
   PubMed Web of Science ®Google Scholar
• CoyleHCloughPCooperPMohanrajRClinical experience with perampanel: focus on psychiatric adverse effectsEpilepsy Behav20144119319625461214
   PubMed Web of Science ®Google Scholar
• FaulknerMABurkeRASafety profile of two novel antiepileptic agents approved for the treatment of refractory partial seizures: ezogabine (retigabine) and perampanelExpert Opin Drug Saf201312684785523883095
   PubMed Web of Science ®Google Scholar
• HoppnerACFauserSKerlingFClinical course of intoxication with the new anticonvulsant drug perampanelEpileptic Disord201315336236424001596
   PubMed Web of Science ®Google Scholar
• HuberBIncreased risk of suicidality on perampanel (Fycompa®)?Epilepsy Behav201431717224361765
   PubMed Web of Science ®Google Scholar
• ShimabukuroKGibbonFKerstetterJTinsleyCAshwalSDRESS associated with perampanel administration in a child with drug-resistant epilepsyNeurology201483232188218925361780
   PubMed Web of Science ®Google Scholar
• EU0031-crushing and dissolving Fycompa, alternative routes of administration.pdf Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002434/WC500130815.pdfAccessed July 1, 2015
   Google Scholar
• No authors listedPerampanel (Fycompa) for epilepsyMed Lett Drugs Ther201456143591024662975
   PubMed Web of Science ®Google Scholar
• RektorIPerampanel, a novel, non-competitive, selective AMPA receptor antagonist as adjunctive therapy for treatment-resistant partial-onset seizuresExpert Opin Pharmacother201314222523523259931
   PubMed Web of Science ®Google Scholar
• TempletonDPharmacokinetics of perampanel, a highly selective AMPA-type glutamate receptor antagonistEpilepsia200950suppl 1198
   Google Scholar
• GidalBEMajidOFerryJThe practical impact of altered dosing on perampanel plasma concentrations: pharmacokinetic modeling from clinical studiesEpilepsy Behav20143561224785428
   PubMed Web of Science ®Google Scholar
• CramerJVachonLDesforgesCSussmanNMDose frequency and dose interval compliance with multiple antiepileptic medications during a controlled clinical trialEpilepsia19953611111111177588455
   PubMed Web of Science ®Google Scholar
• ParientiJBangsbergDRVerdonRGardnerEMBetter adherence with once-daily antiretroviral regimens: a meta-analysisClin Infect Dis200948448448819140758
   PubMed Web of Science ®Google Scholar
• SainiSDSchoenfeldPKaulbackKDubinskyMCEffect of medication dosing frequency on adherence in chronic diseasesAm J Manag Care2009156e22e3319514806
   PubMed Web of Science ®Google Scholar
• ClaxtonAJCramerJPierceCA systematic review of the associations between dose regimens and medication complianceClin Ther20012381296131011558866
   PubMed Web of Science ®Google Scholar
• LeppikIEWechslerRTWilliamsBYangHZhouSLaurenzaAEfficacy and safety of perampanel in the subgroup of elderly patients included in the phase III epilepsy clinical trialsEpilepsy Res201511021622025616475
   PubMed Web of Science ®Google Scholar
• DoltonEChoudryAPerampanel and challenging behaviour in intellectual disability and epilepsy: a management dilemmaCase Rep Psychiatry2014201413
   Google Scholar
• SteinhoffBJHamerHTrinkaEA multicenter survey of clinical experiences with perampanel in real life in Germany and AustriaEpilepsy Res2014108598698824721197
   PubMed Web of Science ®Google Scholar
• RogawskiMAAMPA receptors as a molecular target in epilepsy therapyActa Neurol Scand2013127918
   Web of Science ®Google Scholar
• KraussGLPeruccaEBen-MenachemEPerampanel, a selective, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: Interim results from phase III, extension study 307Epilepsia201354112613422905878
   PubMed Web of Science ®Google Scholar
• HellwigSMamalisPFeigeBSchulze-BonhageAvan ElstLTPsychiatric comorbidity in patients with pharmacoresistant focal epilepsy and psychiatric outcome after epilepsy surgeryEpilepsy Behav201223327227922341961
   PubMed Web of Science ®Google Scholar
• WuTNagayaYHanadaTPharmacodynamic and pharmacokinetic interactions of perampanel and other antiepileptic drugs in a rat amygdala kindling modelSeizure201423973273924997072
   PubMed Web of Science ®Google Scholar
• GidalBEFerryJMajidOHusseinZConcentration-effect relationships with perampanel in patients with pharmacoresistant partial-onset seizuresEpilepsia20135481490149723772853
   PubMed Web of Science ®Google Scholar